Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyanobacterial extract L26-O
- Development stage
- Preclinical
- Lead developer
- University of Helsinki
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Cyanobacterial extract L26-O is a research-stage organic extract derived from the cyanobacterium *Anabaena* (strain HAN 21/1), which was originally isolated from a gastropod in the Baltic Sea. Identified in a 2014 screening study, the extract demonstrates potent pro-apoptotic activity against acute myeloid leukemia (AML) cell lines, including rat IPC-81 and human Molm-13 cells. Its primary mechanism involves the induction of apoptosis through the Bcl-2-mediated pathway, notably allowing it to overcome chemoresistance in cells that overexpress the anti-apoptotic protein Bcl-2. The extract does not exhibit microcystin-like toxicity and its activity is independent of p53 status, making it a potential lead for the development of novel AML therapeutics.
- Other names
- Anabaena HAN 21/1 extract
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on cyanobacterial extract L26-O.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyanobacterial extract L26-O.